2019 1st Line Systemic Therapy for Metastatic Urothelial Carcinoma: Cisplatin as SoC, Pembro Mono as Alternative for Cis-Ineligible, Chemo +/- Atezolizumab vs. Atezolizumab Alone, Enfortumab Vedotin + Pembro, and Subsequent Therapies

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

2019 1st Line Systemic Therapy for Metastatic Urothelial Carcinoma: Cisplatin as SoC, Pembro Mono as Alternative for Cis-Ineligible, Chemo +/- Atezolizumab vs. Atezolizumab Alone, Enfortumab Vedotin + Pembro, and Subsequent Therapies

By Fox Chase Updates in Bladder and Kidney Cancer 2019 FEATURING Elizabeth R. Plimack

437 views

November 22, 2019

Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA

Dr. Plimack is a ...
read more ↘ Professor in the Department of Hematology/Oncology, Chief of the Division of Genitourinary Medical Oncology and Director of Genitourinary Clinical Research at Fox Chase Cancer Center. She is an expert on the treatment of genitourinary malignancies with a focus on bladder and kidney cancers. Her research efforts are directed towards the discovery of novel therapeutic approaches and predictive biomarkers for patients with bladder and kidney cancers. Dr. Plimack has extensive clinical trial experience with immunotherapies and novel combination therapies. She serves on the NCCN guidelines panels for bladder, kidney and prostate cancer, the Bladder Cancer Advocacy Network Management and Think Tank Steering Committees, and the American Joint Committee on Cancer (AJCC) Urinary Tract Expert Panel.

Dr. Plimack completed her medical degree and residency in internal medicine at New York University School of Medicine. She went on to complete a medical oncology fellowship at MD Anderson Cancer Center, and received a Master’s degree in patient-based biologic research from the University of Texas Graduate School of Biomedical Science.
↖ read less

1 Comment